Galectin Therapeutics (GALT) News Today → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free GALT Stock Alerts $3.50 -0.01 (-0.28%) (As of 05/1/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGalectin Therapeutics Incmoney.usnews.com - April 30 at 3:21 PMJames C. Czirr Sells 21,323 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stockamericanbankingnews.com - April 27 at 5:38 AMInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells 21,323 Shares of Stockinsidertrades.com - April 26 at 6:11 AMGalectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells $65,248.38 in Stockmarketbeat.com - April 25 at 1:11 PMGalectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving Average of $2.09americanbankingnews.com - April 24 at 3:26 AMGalectin Therapeutics Inc GALTmorningstar.com - April 20 at 12:14 AMShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Rises By 5.1%marketbeat.com - April 16 at 7:36 PMTraders Purchase Large Volume of Galectin Therapeutics Call Options (NASDAQ:GALT)marketbeat.com - April 11 at 11:37 AMGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of Belapectinmarkets.businessinsider.com - April 9 at 3:03 PMGalectin Therapeutics (NASDAQ:GALT) Earns "Buy" Rating from HC Wainwrightmarketbeat.com - April 9 at 12:12 PMGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisfinance.yahoo.com - April 9 at 10:03 AMGALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023investorplace.com - April 5 at 8:52 AMFY2025 Earnings Forecast for Galectin Therapeutics Inc. (NASDAQ:GALT) Issued By HC Wainwrightmarketbeat.com - April 4 at 9:44 AMGalectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 3 at 8:56 AMAnalysts Set Expectations for Galectin Therapeutics Inc.'s FY2028 Earnings (NASDAQ:GALT)marketbeat.com - April 3 at 6:46 AMBuy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stabilitymarkets.businessinsider.com - April 2 at 1:55 AMGalectin Therapeutics (NASDAQ:GALT) Lifted to "Hold" at StockNews.commarketbeat.com - April 1 at 11:08 PMGalectin Therapeutics (NASDAQ:GALT) Rating Reiterated by HC Wainwrightmarketbeat.com - April 1 at 1:38 PMGalectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 29 at 5:00 PMWhat retail stores are open Easter 2024? Details on Walmart, Target, Macy's, Kohl's, moremsn.com - March 29 at 9:17 AMGalectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developmentsfinance.yahoo.com - March 29 at 9:17 AMGalectin Therapeutics Reports 2023 Financial Results and Provides Business Updateglobenewswire.com - March 29 at 8:00 AMGalectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above 200-Day Moving Average of $1.89marketbeat.com - March 26 at 4:11 AMGalectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Pointseekingalpha.com - March 20 at 10:52 PMGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to Sellmarketbeat.com - March 18 at 11:22 PMMadrigal granted FDA approval for NASH therapymsn.com - March 14 at 4:06 PMLiver drug developers outperform as U.S. awaits first NASH drugmsn.com - March 13 at 2:10 PMGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Developmentglobenewswire.com - March 12 at 8:00 AMGalectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above 200 Day Moving Average of $1.85marketbeat.com - March 7 at 3:24 AMGALT Galectin Therapeutics Inc.seekingalpha.com - February 29 at 5:20 AMRetail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%finance.yahoo.com - February 21 at 10:01 AMArce’s Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial Outlookmarkets.businessinsider.com - November 14 at 10:08 PMGalectin Therapeutics GAAP EPS of -$0.24msn.com - November 13 at 5:28 PMGalectin Therapeutics: Q3 Earnings Insightsbenzinga.com - November 13 at 12:28 PMGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Updatefinance.yahoo.com - November 13 at 12:28 PMUPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Updatefinance.yahoo.com - November 13 at 12:28 PMGalectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023finance.yahoo.com - November 13 at 12:28 PMGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDfinance.yahoo.com - November 3 at 10:42 AMGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023finance.yahoo.com - October 23 at 8:07 AMGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directorsfinance.yahoo.com - October 12 at 12:40 PMGalectin Therapeutics Inc. (PHPN.F)finance.yahoo.com - October 10 at 8:11 AMGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosisfinance.yahoo.com - October 3 at 11:34 AMGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023finance.yahoo.com - September 26 at 9:03 AMGalectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insidersfinance.yahoo.com - September 14 at 8:38 AMGalectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023finance.yahoo.com - September 13 at 5:37 PMGalectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Crossfinance.yahoo.com - September 11 at 5:57 PMGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023finance.yahoo.com - September 7 at 6:43 PMWhat Makes Galectin Therapeutics Inc. (GALT) a New Buy Stockfinance.yahoo.com - August 17 at 6:42 PMGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Updatefinance.yahoo.com - August 14 at 6:23 PMGalectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buyingbenzinga.com - July 22 at 2:43 PM Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here GALT Media Mentions By Week GALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼0.370.35▲Average Medical News Sentiment GALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼81▲GALT Articles Average Week Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OVID News OGI News MACK News CDT News RENB News PRLD News ACRV News FHTX News TRVI News XBIT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GALT) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
